- Home
- INKT vs PULM Comparison
INKT vs PULM Comparison
Compare INKT & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- PULM
- Stock Information
- Founded
- INKT 2017
- PULM 2003
- Country
- INKT United States
- PULM United States
- Employees
- INKT N/A
- PULM N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- PULM Health Care
- Exchange
- INKT Nasdaq
- PULM Nasdaq
- Market Cap
- INKT 75.7M
- PULM 20.5M
- IPO Year
- INKT 2021
- PULM N/A
- Fundamental
- Price
- INKT $16.54
- PULM $5.57
- Analyst Decision
- INKT Hold
- PULM
- Analyst Count
- INKT 3
- PULM 0
- Target Price
- INKT $37.50
- PULM N/A
- AVG Volume (30 Days)
- INKT 3.0M
- PULM 10.9K
- Earning Date
- INKT 08-12-2025
- PULM 08-12-2025
- Dividend Yield
- INKT N/A
- PULM N/A
- EPS Growth
- INKT N/A
- PULM N/A
- EPS
- INKT N/A
- PULM N/A
- Revenue
- INKT N/A
- PULM $1,921,000.00
- Revenue This Year
- INKT N/A
- PULM N/A
- Revenue Next Year
- INKT N/A
- PULM $134.88
- P/E Ratio
- INKT N/A
- PULM N/A
- Revenue Growth
- INKT N/A
- PULM N/A
- 52 Week Low
- INKT $4.56
- PULM $1.78
- 52 Week High
- INKT $76.00
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- INKT 49.27
- PULM 36.25
- Support Level
- INKT $16.02
- PULM $5.20
- Resistance Level
- INKT $20.25
- PULM $6.15
- Average True Range (ATR)
- INKT 8.31
- PULM 0.30
- MACD
- INKT -1.23
- PULM -0.05
- Stochastic Oscillator
- INKT 0.86
- PULM 22.70
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).